Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience
复制标题
DOI：
10.1016/j.lungcan.2010.12.007
复制
发表时间：
2011-08-01
期刊：
影响因子：
5.3
通讯作者：
Jiang, Jiunn-Song
中科院分区：
文献类型：
--
作者：
Chang, Chih-Chia;Chi, Kwan-Hwa;Jiang, Jiunn-Song
背景：前列酪氨酸激酶抑制剂(TKI)已被证明对台湾选择性晚期肺癌患者有效。我们假设在TKI治疗期间早期结合放射治疗将减少耐药机会并延长无进展生存期(PFS)。方法：本研究包括25例对TKI治疗有反应的IIIb或IV期非鳞状细胞非小细胞肺癌(NSqCLC)患者。在TKI治疗过程中进行多靶点放射治疗。放射治疗包括低分割计划，剂量为40-50Gy16-20次，用于个体化转移灶。结果：患者的中位随访期为30个月(9-62个月)。在23名IV期患者中，9名患者患有寡转移瘤(
Background: Upfront tyrosine kinase inhibitor (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. We hypothesized that early integration of radiotherapy during TKI treatment would decrease the chance of drug resistance and prolong progression-free survival (PFS).Methods: This study included 25 patients with stage IIIb or IV non-squamous cell, non-small cell lung cancer (NSqCLC) who responded to upfront TKI treatment. Multi-target radiotherapy was administered during the TKI treatment course. Tomotherapy comprising a hypofractionated schedule with a dose of 40-50 Gy in 16-20 fractions was used for individual metastatic lesions.Results: The patients' median follow-up duration was 30 months (range, 9-62 months). Of the 23 patients who had stage IV disease, 9 had oligometastases (